Refile: West Pharmaceutical Q2 sales beats on biologics, HVP growth; raises outlook

West Pharmaceutical Services

23/07/2026 11:13

Corrects to HVP, from HPV, in headline

    

    Overview
  
Injectable solutions provider's Q2 net sales rose 13.8%, beating analyst expectations
Q2 adjusted EPS beat consensus, up 28.8% year-over-year
Company raised full-year 2026 net sales and adjusted EPS guidance

    

    Outlook
  
West Pharmaceutical raises full-year 2026 net sales guidance to $3.345 bln-$3.380 bln
Company lifts full-year 2026 adjusted-diluted EPS forecast to $8.85-$9.05
West Pharmaceutical sees Q3 2026 net sales of $820 mln-$835 mln and adjusted EPS of $2.14-$2.24

    

    Result Drivers
  
HVP COMPONENTS & BIOLOGICS - Co said Q2 organic sales growth was driven by High-Value Product Components, with continued strength in Biologics and a favorable mix shift from HVP upgrades including Annex 1
GLP-1 ELASTOMERS - Ongoing growth in GLP-1 elastomers contributed to sales gains, per CEO Eric Green
MARGIN EXPANSION - Strong sales growth led to operating income margin expansion compared to prior year

    
Company press release: ID:nPn5T2ZDLa

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Net sales
Beat
$872.30 mln
$838.59 mln (11 Analysts)
Q2 Adjusted EPS
Beat
$2.37
$2.08 (11 Analysts)
Q2 EPS
 
$2.15
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for West Pharmaceutical Services Inc is $375.00, about 4.6% above its July 22 closing price of $358.41
The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 30 three months ago

    

    Reuters Recommended Reads
  
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook
July 23 - Sartorius beats half-year earnings expectations aided by tariff refunds
July 22 - Switzerland's Lonza H1 sales rise, lifts FY core EBITDA margin forecast

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)